When the U.S. Food and Drug Administration asked American Home Products to pull fenfluramine (Pondimin) and dexfenfluramine (Redux) from the market on 15 September 1997, it ended a weight-loss phenomenon that had been built on an off-label pairing the agency had never approved and a long-term safety record nobody had assembled. Fen-Phen — the colloquial yoking of fenfluramine, a serotonin-releasing anorectic approved in 1973, with phentermine, a stimulant approved in 1959 — had become, by 1996, one of the most prescribed drug ideas in America: roughly 18 million prescriptions in that year alone and an estimated 6 million users, exposure on the order of 61 million patient-months. The gap between the promise of easy, doctor-blessed thinness and the harm was a class of damage that does not announce itself: scarred heart valves and, more rarely, lethal pulmonary hypertension.
The combination’s popularity rested on a 1992 study and on a regulatory permission slip that was never granted. The FDA had approved fenfluramine and phentermine each as standalone short-term anorectics; it had never approved their combination, nor either drug for the open-ended, cosmetic, multi-year use that fen-phen clinics dispensed. The 1996 approval of dexfenfluramine — the more potent right-handed isomer, sold as Redux and the first new prescription weight-loss drug in 23 years — poured accelerant on the market, despite an FDA advisory committee that had initially voted against it and known pulmonary-hypertension concerns in European data.
The verdict is plain at the outset. A combination the agency never sanctioned, marketed for a use it never authorized, reached millions before any long-term cardiac safety study existed; the damage was found not by the regulator or the manufacturer but by Mayo Clinic cardiologists who noticed a pattern. Their report, published in the New England Journal of Medicine on 28 August 1997, described 24 women with no prior cardiac history who had developed an unusual valvular disease — leaflets thickened with a glistening, carcinoid-like plaque — after taking fen-phen. The drug came off the market eighteen days later.
What followed was, for its era, the largest product-liability reckoning in pharmaceutical history. American Home Products (renamed Wyeth in 2002) agreed to a $3.75 billion national class settlement in 1999, then watched its total liability climb past $21 billion as tens of thousands of plaintiffs opted out, and the case became the standard byword for what happens when an off-label combination and a direct-to-consumer obesity market outrun the safety science that should have preceded them.
When the U.S. Food and Drug Administration issued its Drug Bulletin on 25 November 1971 declaring diethylstilbestrol contraindicated in pregnancy, it was retracting an indication it had blessed twenty-four years earlier for a drug that had never been shown to work — and the trigger was not a failure of efficacy but a cancer in a generation that had been exposed before birth. DES, the first orally active synthetic estrogen, was synthesized in 1938 in the Middlesex Hospital laboratory of Sir Edward Charles Dodds in London, deliberately left unpatented, and promoted from the mid-1940s by the Harvard husband-and-wife team of George and Olive Smith as a means of preventing miscarriage by “building up” placental hormones. The gap between that promise and the documented record is among the widest in pharmaceutical history: the drug did not prevent miscarriage, and it carried a harm that would not become visible for roughly two decades.
The signal arrived in April 1971, when Arthur Herbst, Howard Ulfelder, and David Poskanzer published a case-control study in The New England Journal of Medicine reporting eight cases of clear-cell adenocarcinoma of the vagina in young women aged 15 to 22 — a tumor so rare in that age group that a cluster of eight was itself an anomaly. Seven of the eight mothers had taken DES while pregnant; only one of thirty-two matched controls had. The association was overwhelming, with the odds of chance occurrence below one in one hundred thousand. The mechanism was transplacental: a drug given to the mother had reached across the placenta and altered the developing reproductive tract of the fetus, with the consequence emerging only at puberty.
The verdict is therefore plain at the outset. An estimated five to ten million Americans — pregnant women and the children born of those pregnancies — were exposed to DES between roughly 1940 and 1971 on the strength of an indication that controlled trials had already shown to be useless. As early as 1953, William Dieckmann’s randomized, double-blind study at the University of Chicago Lying-In Hospital had demonstrated that DES did not reduce miscarriage, premature birth, or neonatal death; prescribing continued for eighteen more years regardless. The drug was not so much a wonder therapy that went wrong as an unproven one that was never stopped.
What remains is a two-generation injury with a long tail. DES daughters carry roughly forty times the baseline risk of clear-cell adenocarcinoma, develop it at a rate near 1 in 1,000, and face elevated rates of infertility, ectopic pregnancy, premature delivery, and breast cancer; DES sons and even a third generation have shown reproductive anomalies. The episode became the founding case study of the transplacental carcinogen and a standing rebuke to the idea that a drug’s safety can be judged only in the patient who swallows it.
When the U.S. Food and Drug Administration asked Warner-Lambert to pull Rezulin from the market on 21 March 2000, it ended a three-year arc in which a celebrated first-in-class diabetes pill killed at least 63 people through liver failure while the warning that should have stopped it had been visible from before launch. Rezulin (troglitazone), the first thiazolidinedione — an oral “insulin sensitizer” acting on the PPAR-gamma receptor — was approved on 29 January 1997 and marketed as a breakthrough that let type 2 diabetics use their own insulin more effectively. The gap between that promise and the harm was not subtle: the drug produced idiosyncratic, sometimes fulminant hepatotoxicity, and Britain’s Glaxo Wellcome withdrew it from the U.K. market on 1 December 1997 — barely ten months after the U.S. approval — while the FDA kept it on American shelves for another twenty-eight months.
The signal was institutional, not merely clinical. The FDA medical officer originally assigned to the application, Dr. John Gueriguian, had recommended against approval over cardiac and liver concerns; he was removed from the review on 4 November 1996, and his negative analysis was purged from the official record before the drug was cleared on an expedited timeline. Within the first year of marketing, serious hepatotoxicity reports accumulated, and an internal FDA memorandum cited 135 reports of serious liver injury by late 1997. Public Citizen’s Health Research Group, led by Dr. Sidney Wolfe, petitioned for withdrawal in July 1998, asking the agency how many more Americans would have to die or need transplants.
The verdict is therefore plain at the outset: a profitable, regulator-blessed, heavily prescribed medicine reached nearly two million Americans while the evidence that condemned it — a foreign withdrawal, a buried internal review, mounting death reports, and an outside petition — sat fully legible in the record. The FDA’s response was incrementalism: four label changes between 1997 and 1999 adding ever-stricter liver-monitoring instructions that real-world prescribing could not reliably execute, rather than removal.
What finally forced the withdrawal was arithmetic the labels could not fix. Once two safer thiazolidinediones — rosiglitazone and pioglitazone — reached the market in 1999 without the same fatal liver signal, Rezulin’s risk-benefit case collapsed, and the FDA requested its removal on 21 March 2000. Litigation followed: Warner-Lambert, absorbed by Pfizer in 2000, ultimately resolved roughly 35,000 claims for an estimated $750 million, and “Rezulin” became a byword for how a buried safety review and an ignored foreign recall can keep a lethal drug on the market for years.
When Abbott Laboratories agreed on 8 October 2010 to pull Meridia (sibutramine) from the U.S. market at the request of the Food and Drug Administration, the company maintained that the drug remained safe for its approved population; the documented record shows that the very trial regulators had ordered Abbott to run had measured the opposite, and had measured it in the patients most likely to receive a weight-loss prescription. Sibutramine, a serotonin–norepinephrine reuptake inhibitor approved by the FDA in November 1997 as an appetite suppressant for obese patients, was instead found to raise the risk of nonfatal heart attack and stroke by roughly 16 percent while delivering a placebo-adjusted weight loss of only about 2.5 percent of body weight after five years.
The gap between promise and harm was not a late surprise; it was the product of a contradiction visible at approval. Sibutramine worked by raising levels of norepinephrine and serotonin to blunt appetite, and that same sympathetic activation predictably raised blood pressure and heart rate. A drug marketed to obese patients — a group already loaded with cardiovascular risk — carried a mechanism that pushed the cardiovascular system in exactly the wrong direction. The FDA approved it anyway on a surrogate endpoint, pounds lost on a scale, and deferred the question of whether those pounds came at the cost of hearts.
The answer arrived in the Sibutramine Cardiovascular Outcomes Trial, or SCOUT, a roughly 10,744-patient study that European regulators had demanded as a post-marketing condition. After a mean of 3.4 years of follow-up, the primary composite outcome — nonfatal myocardial infarction, nonfatal stroke, resuscitated cardiac arrest, and cardiovascular death — occurred in 11.4 percent of the sibutramine group versus 10.0 percent of placebo (hazard ratio 1.16; p=0.015). The verdict is therefore plain at the outset: a drug whose central trade-off was legible from its pharmacology in 1997 was permitted to circulate for thirteen years until the safety trial its makers were compelled to conduct confirmed the harm.
What followed was a coordinated transatlantic revocation rather than a courtroom reckoning. The European Medicines Agency suspended sibutramine on 21 January 2010; the FDA recommended against its use and accepted Abbott’s voluntary withdrawal that October. Sibutramine became the byword for a specific failure mode in obesity medicine: approving a drug on a weight surrogate when its own mechanism telegraphs a cardiovascular hazard, then waiting a decade-plus for a mandated outcomes trial to state the obvious.
When Joseph Califano, Secretary of Health, Education and Welfare, signed the order suspending phenformin on 25 July 1977, he was invoking a power Congress had granted the Food and Drug Administration fifteen years earlier and which no official had ever used: the declaration that an approved medicine was an “imminent hazard to the public health.” Phenformin (phenethylbiguanide), synthesized in 1957 by a team including Seymour Shapiro at the U.S. Vitamin Corporation and marketed in the United States from 1959 by Ciba-Geigy as DBI, had been prescribed to control adult-onset diabetes for nearly two decades. It was withdrawn not because it failed to lower blood sugar — it did that adequately — but because it could quietly poison the body with lactic acid, a complication that killed roughly one of every two patients it reached.
The gap between the promise and the harm was the gap between a surrogate benefit and a survival outcome. Phenformin reliably reduced glycemia, the number physicians could see on a chart; what it did not reliably do was keep patients alive. The biguanide’s mechanism — pushing cellular metabolism toward anaerobic glycolysis — produced excess lactate, and in patients with even modest kidney or heart impairment that lactate could accumulate into a metabolic catastrophe. Phenformin-associated lactic acidosis ran at roughly 40 to 64 cases per 100,000 patient-years, and once it occurred it was fatal in approximately half of cases. The drug treated a chronic disease by trading a visible, manageable problem for an occasional, lethal one.
The verdict was therefore plain long before the suspension. As early as 1959 — the same year U.S. marketing began — the literature linked biguanides to lactic acidosis. In 1971 the federally funded University Group Diabetes Program (UGDP) terminated its phenformin arm after finding excess total and cardiovascular mortality, roughly double that of the placebo and insulin groups combined. By October 1976 the FDA’s own Endocrinology and Metabolism Advisory Committee had recommended removal. The harm sat in the published record for years while ~385,000 Americans were still taking the drug in 1977.
What forced the cord was not the agency but a consumer group and a lawyer’s petition. Ralph Nader’s Health Research Group petitioned for suspension on 22 April 1977; Califano acted in July; the drug was off the U.S. market by 15 November 1978. The episode became the founding precedent for emergency drug suspension, the cautionary prologue to its safer sister biguanide metformin, and the textbook case of how a medicine can be effective on the metric it was sold on and still be a net killer.